Cargando…
Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase
Liver pyruvate kinase (PKL) has recently emerged as a new target for non-alcoholic fatty liver disease (NAFLD), and inhibitors of this enzyme could represent a new therapeutic option. However, this breakthrough is complicated by selectivity issues since pyruvate kinase exists in four different isofo...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9919951/ https://www.ncbi.nlm.nih.gov/pubmed/36771285 http://dx.doi.org/10.3390/nu15030577 |
_version_ | 1784886950384107520 |
---|---|
author | Battisti, Umberto Maria Gao, Chunixa Akladios, Fady Kim, Woonghee Yang, Hong Bayram, Cemil Bolat, Ismail Kiliclioglu, Metin Yuksel, Nursena Tozlu, Ozlem Ozdemir Zhang, Cheng Sebhaoui, Jihad Iqbal, Shazia Shoaie, Saeed Hacimuftuoglu, Ahmet Yildirim, Serkan Turkez, Hasan Uhlen, Mathias Boren, Jan Mardinoglu, Adil Grøtli, Morten |
author_facet | Battisti, Umberto Maria Gao, Chunixa Akladios, Fady Kim, Woonghee Yang, Hong Bayram, Cemil Bolat, Ismail Kiliclioglu, Metin Yuksel, Nursena Tozlu, Ozlem Ozdemir Zhang, Cheng Sebhaoui, Jihad Iqbal, Shazia Shoaie, Saeed Hacimuftuoglu, Ahmet Yildirim, Serkan Turkez, Hasan Uhlen, Mathias Boren, Jan Mardinoglu, Adil Grøtli, Morten |
author_sort | Battisti, Umberto Maria |
collection | PubMed |
description | Liver pyruvate kinase (PKL) has recently emerged as a new target for non-alcoholic fatty liver disease (NAFLD), and inhibitors of this enzyme could represent a new therapeutic option. However, this breakthrough is complicated by selectivity issues since pyruvate kinase exists in four different isoforms. In this work, we report that ellagic acid (EA) and its derivatives, present in numerous fruits and vegetables, can inhibit PKL potently and selectively. Several polyphenolic analogues of EA were synthesized and tested to identify the chemical features responsible for the desired activity. Molecular modelling studies suggested that this inhibition is related to the stabilization of the PKL inactive state. This unique inhibition mechanism could potentially herald the development of new therapeutics for NAFLD. |
format | Online Article Text |
id | pubmed-9919951 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99199512023-02-12 Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase Battisti, Umberto Maria Gao, Chunixa Akladios, Fady Kim, Woonghee Yang, Hong Bayram, Cemil Bolat, Ismail Kiliclioglu, Metin Yuksel, Nursena Tozlu, Ozlem Ozdemir Zhang, Cheng Sebhaoui, Jihad Iqbal, Shazia Shoaie, Saeed Hacimuftuoglu, Ahmet Yildirim, Serkan Turkez, Hasan Uhlen, Mathias Boren, Jan Mardinoglu, Adil Grøtli, Morten Nutrients Article Liver pyruvate kinase (PKL) has recently emerged as a new target for non-alcoholic fatty liver disease (NAFLD), and inhibitors of this enzyme could represent a new therapeutic option. However, this breakthrough is complicated by selectivity issues since pyruvate kinase exists in four different isoforms. In this work, we report that ellagic acid (EA) and its derivatives, present in numerous fruits and vegetables, can inhibit PKL potently and selectively. Several polyphenolic analogues of EA were synthesized and tested to identify the chemical features responsible for the desired activity. Molecular modelling studies suggested that this inhibition is related to the stabilization of the PKL inactive state. This unique inhibition mechanism could potentially herald the development of new therapeutics for NAFLD. MDPI 2023-01-22 /pmc/articles/PMC9919951/ /pubmed/36771285 http://dx.doi.org/10.3390/nu15030577 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Battisti, Umberto Maria Gao, Chunixa Akladios, Fady Kim, Woonghee Yang, Hong Bayram, Cemil Bolat, Ismail Kiliclioglu, Metin Yuksel, Nursena Tozlu, Ozlem Ozdemir Zhang, Cheng Sebhaoui, Jihad Iqbal, Shazia Shoaie, Saeed Hacimuftuoglu, Ahmet Yildirim, Serkan Turkez, Hasan Uhlen, Mathias Boren, Jan Mardinoglu, Adil Grøtli, Morten Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase |
title | Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase |
title_full | Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase |
title_fullStr | Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase |
title_full_unstemmed | Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase |
title_short | Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase |
title_sort | ellagic acid and its metabolites as potent and selective allosteric inhibitors of liver pyruvate kinase |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9919951/ https://www.ncbi.nlm.nih.gov/pubmed/36771285 http://dx.doi.org/10.3390/nu15030577 |
work_keys_str_mv | AT battistiumbertomaria ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase AT gaochunixa ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase AT akladiosfady ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase AT kimwoonghee ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase AT yanghong ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase AT bayramcemil ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase AT bolatismail ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase AT kiliclioglumetin ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase AT yukselnursena ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase AT tozluozlemozdemir ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase AT zhangcheng ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase AT sebhaouijihad ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase AT iqbalshazia ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase AT shoaiesaeed ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase AT hacimuftuogluahmet ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase AT yildirimserkan ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase AT turkezhasan ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase AT uhlenmathias ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase AT borenjan ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase AT mardinogluadil ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase AT grøtlimorten ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase |